Items Tagged ‘immunotherapy’

October 4th, 2016

A New Drug That ‘Wakes Up’ Immune System Appears to Fight Pancreatic Cancer

By

A novel drug, IMM-101 has extended the lives of some people with metastatic pancreatic cancer and appears to have minimal side-effects. Doctors describe IMM-101 as “waking up” the immune system to attack cancer. Patients who were given the new immunotherapy drug actually felt better than those who were on standard chemotherapy, said Angus Dalgleish, professor […]

View full entry

Tags: gemcitabine, IMM-101 Gemzar, immunotherapy, News, Pancreatic Cancer


June 30th, 2016

Tecentriq™ Plus Abraxane® Effective Combo in Difficult to Treat Breast Cancer

By

The combination of the immune stimulating agent Tecentriq™ (atezolizumab), plus the chemotherapy agent Abraxane® (nab-paclitaxel) is effective in providing anti-cancer responses among patients with advanced triple-negative breast cancer (TNBC). These results were recently reported at the 2016 annual meeting of the American Society of Clinical Oncology (ASCO). Approximately 10-20% of breast cancers are referred to […]

View full entry

Tags: Breast Cancer, immunotherapy, Metastatic Breast Cancer, News, Recurrent Breast Cancer, Tecentriq, tnbc, Triple Negative Breast Cancer


June 6th, 2016

A New Standard of Care of Treatment for Resectable Pancreatic Cancer?

By

According to experts at the American Society of Clinical Oncology (ASCO) 2016 Annual Meeting the European Study Group for Pancreatic Cancer (ESPAC)-4 has presented results that will change the management of pancreatic cancer. Pancreatic cancer is one of the deadliest forms of cancer. Each year, approximately 43,000 people are diagnosed with pancreatic cancer in the […]

View full entry

Tags: 2016, asco, capecitabine, ESPAC-4, European Study Group for Pancreatic Cancer, gemcitabine, gemzar, immunotherapy, mesothelin-directed cells, News, Pancreatic Cancer, Xeloda


June 6th, 2016

PD-1 Inhibitor Keytruda® Combined with Chemotherapy Promising in Lung Cancer Will be Evaluated in Larger Clinical Trials

By

According to experts at the American Society of Clinical Oncology (ASCO) 2016 Annual Meeting in Chicago, new data evaluating Keytruda® (pembrolizumab) in combination with chemotherapy appears promising for the treatment of non-small cell lung cancer (NSCLC). Based on these initial results, two comparative clinical trials have been initiated. The programmed death (PD-1) inhibitor Keytruda (pembrolizumab) […]

View full entry

Tags: fda, immunotherapy, KEYNOTE-189, keytruda, Lung Cancer, Lung Cancer - Non-Small Cell, News, non-small cell lung cancer, nsclc, PD-1 inhibitor, pembrolizumab


June 6th, 2016

Two-Drug Immunotherapy Deemed Safe for Small Cell Lung Cancer Patients, Moffitt Study Shows

By

Small cell lung cancer (SCLC) represents approximately 14 percent of all types of lung cancer. Many patients with SCLC respond to initial chemotherapy; however, they eventually relapse and develop progressive disease that has no effective treatment options. A new Moffitt Cancer study being presented at the ASCO Annual Meeting in Chicago and published in The […]

View full entry

Tags: 2016, asco, Checkmate 032, immunotherapy, ipilmumab, Lung Cancer, Lung Cancer - Small Cell, molecule PD-1, News, nivolumab, sclc, small cell lung cancer


May 23rd, 2016

Genetically Modified Poliovirus Granted “Breakthrough” by FDA for Glioblastoma

By

The United States Food and Drug Administration (FDA) has granted “breakthrough status” designation for the treatment of glioblastoma containing a genetically modified poliovirus. Glioblastoma is an extremely aggressive form of brain cancer, with few patients surviving 5 years following diagnosis. Despite efforts with surgery, chemotherapy, and/or radiation therapy, the overall outcomes for patients with glioblastoma […]

View full entry

Tags: Brain Cancer, breakthrough status, fda, General Brain Cancer, genetically modified polio virus, glioblastoma, immunotherapy, News


January 19th, 2016

Blincyto® is Promising New Treatment Option for Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia

By

Amgen, a biotechnology company, has announced that their immunotherapy drug Blincyto® (blinatumomab) appears promising in the treatment of adults with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL). The company announced findings from a Phase 2 trial in a recent press release. Acute lymphoblastic leukemia is a fast-growing cancer of the white blood cells. Relapsed/refractory ALL in […]

View full entry

Tags: Acute Lymphoblastic Leukemia, acute lymphoblastic lymphoma, all, blincyto, cd19, immunotherapy, Leukemia, News, Philadelphia chromosome positive


March 17th, 2015

XBiotech Launches Website and Call Center to Facilitate Recruitment for U.S. Phase III Study of Xilonix™ in Metastatic Colorectal Cancer

By

AUSTIN, Texas, March 12, 2015—XBiotech announced today that it has launched a website and call center to help patients with metastatic colorectal cancer learn about its U.S. Pivotal Phase III clinical trial. The Phase III study named, XilonixTM  Colorectal cancer Immunotherapy Treatment Evaluation (“XCITE”), assesses XBiotech’s True Human™ monoclonal antibody (XilonixTM) for the treatment of […]

View full entry

Tags: Colon Cancer, colorectal cancer, immunotherapy, metastatic colorectal cance, monoclonal antibody, News, Rectal Cancer, Recurrent/Relapsed Rectal Cancer, Stage IV (D)/Relapsed Colon Cancer, Stage IV Rectal Cancer, xbiotech, xcite


December 10th, 2014

Initial Results of PD-1 Checkpoint Inhibitors Evaluated in Triple-Negative Breast Cancer Presented in San Antonio

By

The initial results from a phase 1 trial evaluating the checkpoint inhibitor Keytruda® (pembrolizumab) in patients with heavily pretreated triple-negative breast cancer were recently reported at the San Antonio Breast Cancer Symposium (SABCS). The cancer immunotherapy strategy known as programmed cell death 1 (PD-1) has generated great excitement for its ability to help the immune […]

View full entry

Tags: Breast Cancer, immunotherapy, keytruda, Metastatic Breast Cancer, News, PD-1, Recurrent Breast Cancer, tnbc, Triple Negative Breast Cancer


November 24th, 2014

New Information Helps Understanding Immunotherapy’s Successes—And Its Failures

By

(OMNI- CancerConnect) A collaborative team of leaders in the field of cancer immunology from Memorial Sloan Kettering Cancer Center has made a key discovery that advances the understanding of why some patients respond to ipilimumab, an immunotherapy drug, while others do not.  MSK was at the forefront of the clinical research that brought this CTLA-4 […]

View full entry

Tags: immunotherapy, ipilimumab, Melanoma, News, Recurrent Melanoma, Stage III Melanoma, Stage IV Melanoma, Yervoy


November 20th, 2014

Nivolumab Superior to Chemotherapy in First Phase III Trial as Initial Treatment in Advanced Melanoma

By

The immunotherapy drug nivolumab produces significantly better overall survival than chemotherapy as initial treatment in advanced melanoma, according to findings from its first Phase III study in previously untreated patients. These results were recently published online in the New England Journal of Medicine.[1] Of the more than one million new diagnoses of skin cancer each year, […]

View full entry

Tags: immunotherapy, Melanoma, melaoma, News, nivolumab, PD-1, Recurrent Melanoma, Stage IV Melanoma